[{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"GOVX-B11","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Not Applicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"GeoVax Labs \/ Not Applicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"MVA-MARV-VLP vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GeoVax Labs \/ Not Applicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"GEO-CM01","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ GeoVax","highestDevelopmentStatusID":"4","companyTruncated":"GeoVax Labs \/ GeoVax"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"GEO-CM02","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeoVax Labs \/ Not Applicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GeoVax Labs \/ City of Hope","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ City of Hope"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"EmVenio Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GEO-CM04S1","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GeoVax Labs \/ EmVenio Research","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ EmVenio Research"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Ad\/PNP","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GeoVax Labs \/ Not Applicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Advanced Bioscience laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"MVA-based SARS-CoV-2 Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GeoVax Labs \/ Advanced Bioscience Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Advanced Bioscience Laboratories"}]

Find Clinical Drug Pipeline Developments & Deals by GeoVax Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The partnership will support current Good Manufacturing Practices production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine), a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector p...

                          Brand Name : GEO-CM04S1

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 31, 2023

                          Lead Product(s) : MVA-based SARS-CoV-2 Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Advanced Bioscience laboratories

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GEO-CM04S1 is a synthetic attenuated modified vaccinia Ankara (sMVA) vector vaccine that expresses spike and nucleocapsid antigens of the SARS-CoV-2 (COVID-19) virus.

                          Brand Name : GEO-CM04S1

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          February 15, 2023

                          Lead Product(s) : GEO-CM04S1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : EmVenio Research

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Gedeptin (Ad/PNP) is a gene-directed enzyme prodrug therapy (GDEPT) that results in the formation of the oncolytic agent within the tumor itself, resulting in tumor cell death while significantly limiting systemic exposure.

                          Brand Name : Gedeptin

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          February 07, 2023

                          Lead Product(s) : Ad/PNP,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical tria...

                          Brand Name : COH04S1

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 10, 2022

                          Lead Product(s) : COH04S1

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : City of Hope

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GeoVax’s vaccine design strategy for developing a universal SARS-CoV-2 vaccine and presented efficacy and immunogenicity data for the Company’s lead vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane (M) and Envelope (E) proteins.

                          Brand Name : GEO-CM02

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 17, 2021

                          Lead Product(s) : GEO-CM02

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The Patent License Agreement to GeoVax includes access to NIAID’s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.

                          Brand Name : GEO-CM01

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          October 26, 2020

                          Lead Product(s) : GEO-CM01

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : National Institutes of Health

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The study demonstrated that guinea pigs vaccinated with GeoVax’s developmental MVA-MARV-VLP vaccine were 100% protected against death and disease caused by the Angola strain of Marburg virus.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 03, 2020

                          Lead Product(s) : MVA-MARV-VLP vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : GeoVax is using its GV-MVA-VLPTMvaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 04, 2020

                          Lead Product(s) : COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : An independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV infection.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          February 06, 2020

                          Lead Product(s) : GOVX-B11

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank